Patent application number | Description | Published |
20080262802 | SYSTEM AND METHOD FOR OILFIELD PRODUCTION OPERATIONS - The invention relates to a method of performing production operations. The method includes identifying a plurality of simulators from a group consisting of a wellsite simulator for modeling at least a portion of the wellsite of the oilfield and a non-wellsite simulator for modeling at least a portion of a non-wellsite portion of the oilfield, defining a first strategy template comprising a first condition defined based on a first variable of the plurality of simulators and a first action defined based on a control parameter of the plurality of simulators, wherein execution of the first action during simulation is determined based on the first condition in view of a logical relationship, developing a first strategy for managing the plurality of simulators during simulation, wherein the first strategy is developed using the first strategy template, and selectively simulating the operations of the oilfield using the plurality of simulators based on the first strategy. | 10-23-2008 |
20100185427 | AUTOMATED FIELD DEVELOPMENT PLANNING - A system for automatically optimizing a Field Development Plan (FDP) for an oil or gas field uses a fast analytic reservoir simulator to dynamically model oil or gas production from the entire reservoir over time in an accurate and rapid manner. An objective function defining a Figure of Merit (FoM) for candidate FDPs is maximized, using an optimization algorithm, to determine an optimized FDP in light of physical, engineering, operational, legal and engineering constraints. The objective function for the Figure of Merit, e.g., net present value (NPV) or total production for a given period of time, relies on a production forecast from the fast analytic reservoir simulator for the entire FDP. The position, orientation and dimensions of analytical model elements for the subsurface oil or gas field, as well as the physical properties associated with these elements, correlate to connected flow volume data from a Shared Earth Model (SEM). Uncertainty in the SEM is considered via stochastic sampling. In the presence of uncertainty, the optimum Field Development Plan (FoM) is selected by maximizing an objective function defining a risk-based Figure of Merit for the entire FDP. | 07-22-2010 |
Patent application number | Description | Published |
20130225656 | ANALYZING SEMAPHORIN7A (Sema7A) LEVELS FOR ASSESSING CANCER METASTATIC POTENTIAL AND METHODS OF TREATMENT - Methods, assays, and kits for determining a cancer's (e.g., breast cancer) metastatic potential and tumor aggressiveness in a subject (e.g., a human patient) and for measuring a subject's response to cancer therapy involve analyzing expression of Sema7A in a biological sample from the subject, and correlating increased expression of Sema7A in the biological sample compared to a control sample with metastatic potential of the cancer, wherein the expression of Sema7A is linearly proportional to the metastatic potential of the cancer in the subject. These methods, kits and assays provide for individualized diagnosis and treatment options for cancer (e.g., breast cancer) patients. They can be used independently, or can be combined with additional diagnostic tests and/or prognostic methods. Compositions, kits and methods for treating a subject having cancer (e.g., breast cancer) include administering a composition for inhibiting Sema7A expression or activity to the subject. | 08-29-2013 |
20150111781 | ANALYZING SEMAPHORIN7A (Sema7A) LEVELS FOR ASSESSING CANCER METASTATIC POTENTIAL - Methods, assays, and kits for determining a cancer's (e.g., breast cancer) metastatic potential and tumor aggressiveness in a subject (e.g., a human patient) and for measuring a subject's response to cancer therapy involve analyzing expression of Sema7A in a biological sample from the subject, and correlating increased expression of Sema7A in the biological sample compared to a control sample with metastatic potential of the cancer, wherein the expression of Sema7A is linearly proportional to the metastatic potential of the cancer in the subject. These methods, kits and assays provide for individualized diagnosis and treatment options for cancer (e.g., breast cancer) patients. They can be used independently, or can be combined with additional diagnostic tests and/or prognostic methods. Compositions, kits and methods for treating a subject having cancer (e.g., breast cancer) include administering a composition for inhibiting Sema7A expression or activity to the subject. | 04-23-2015 |
Patent application number | Description | Published |
20100009015 | USE OF CHROMIUM HISTIDINATE FOR TREATMENT OF CARDIOMETABOLIC DISORDERS - Provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising chromium and histidine, chromium histidinate complexes, or combinations thereof, to the individual. | 01-14-2010 |
20100178362 | CHROMIUM COMPLEXES FOR IMPROVEMENT OF MEMORY AND COGNITIVE FUNCTION - A method of treating impaired memory and/or cognitive function by administering one or more chromium complexes, for example chromium picolinate, to an individual in need of improved memory and/or cognitive function. This method is used to improve memory and/or cognitive function associated with various disorders, including Alzheimer's disease, dementia, and mild cognitive impairment (MCI). Chromium complexes for treating memory or cognitive impairment are also disclosed. | 07-15-2010 |
20130101681 | USE OF CHROMIUM HISTIDINATE FOR TREATMENT OF CARDIOMETABOLIC DISORDERS - Provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising chromium and histidine, chromium histidinate complexes, or combinations thereof, to the individual. | 04-25-2013 |
20150272991 | USE OF CHROMIUM HISTIDINATE FOR TREATMENT OF CARDIOMETABOLIC DISORDERS - Provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising chromium and histidine, chromium histidinate complexes, or combinations thereof, to the individual. | 10-01-2015 |
Patent application number | Description | Published |
20080319021 | Inhibition Of Phosphoinositide 3-Kinase Beta - The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase. | 12-25-2008 |
20100069393 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME - The present invention relates generally to therapeutic agents, formulations comprising them and their use in the treatment, amelioration and/or prophylaxis of glioma brain tumours and related conditions. The therapeutic agent comprises two fused 6-membered rings with at least a nitrogen at position 1 and a hydroxyl at position 8. | 03-18-2010 |
20100144693 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) - The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions. | 06-10-2010 |
20110071167 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) - The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions. | 03-24-2011 |
20110110850 | COMPOUNDS FOR THERAPY AND DIAGNOSIS - The present invention relates to a transition metal complex represented by Formula (I) or salts thereof, or to a ligand represented by Formula (H) or salts thereof, wherein X represents a transition metal, preferably Pt, and methods for their use and preparation. In particular, the invention relates to compounds which may possess useful therapeutic activity in treating amyloid diseases, and in particular, Alzheimer's disease. The invention also relates to the use of these compounds in methods of therapy, and diagnosis, and the manufacture of medicaments as well as compositions containing these compounds. | 05-12-2011 |
Patent application number | Description | Published |
20080206312 | Therapeutic Morpholino-Substituted Compounds - Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases. | 08-28-2008 |
20080312233 | Therapeutic Morpholino-Substituted Compounds - Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases. | 12-18-2008 |
Patent application number | Description | Published |
20110182387 | Blind Mechanism for the Joint Estimation of Frequency Offset and Phase Offset for QAM Modulated Signals - A mechanism for jointly correcting carrier phase and carrier frequency errors in a demodulated signal. A computer system may receive samples of a baseband input signal (resulting from QAM demodulation). The computer system may compute values of a cost function J over a grid in a 2D angle-frequency space. A cost function value J(θ,ω) is computed for each point (θ,ω) in the grid by (a) applying a phase adjustment of angle θ and a frequency adjustment of frequency ω to the input signal; (b) performing one or more iterations of the K-means algorithm on the samples of the adjusted signal; (c) generated a sum on each K-means cluster; and (d) adding the sums. The point (θ | 07-28-2011 |
20120207248 | Estimation of Sample Clock Frequency Offset Using Error Vector Magnitude - A low complexity system and method for operating a receiver in order to estimate an offset between the actual sample clock rate 1/T | 08-16-2012 |
20130215986 | Blind Estimation of Frequency and Phase Offsets for Received Signals - A mechanism for jointly correcting carrier phase and carrier frequency errors in a demodulated signal. A computer system may receive samples of a baseband input signal (resulting from QAM demodulation). The computer system may compute values of a cost function J over a grid in a 2D angle-frequency space. A cost function value J(θ,ω) is computed for each point (θ,ω) in the grid by (a) applying a phase adjustment of angle θ and a frequency adjustment of frequency ω to the input signal; (b) performing one or more iterations of the K-means algorithm on the samples of the adjusted signal; (c) generated a sum on each K-means cluster; and (d) adding the sums. The point (θ | 08-22-2013 |
20130216005 | Blind Mechanism for Demodulating Offset QPSK Signals in the Presence of Carrier Phase Error - A computer-implemented system and method for blind demodulation of an offset QPSK input signal, involving repeatedly performing a set of operations, including: (a) applying a phase correction to the input signal based on an estimate of a carrier phase offset of the input signal to obtain a first modified signal; (b) shifting a quadrature component of the first modified signal by half a symbol period relative to an inphase component to obtain a second modified signal; (c) extracting a first sequence of symbols from the second modified signal, where the extraction includes estimating a symbol timing offset from the second modified signal; (d) performing hard-decision demodulation on the first sequence of symbols to obtain a second sequence of reference symbols; (e) computing a phase difference between the first sequence of symbols and second sequence of reference symbols; and (f) updating the carrier phase offset estimate using the phase difference. | 08-22-2013 |
20130230114 | Using Error Vector Magnitude to Estimate Sample Clock Frequency Offset - A low complexity system and method for operating a receiver in order to estimate an offset between the actual sample clock rate 1/T | 09-05-2013 |
20130287147 | Maximizing the Viterbi Winning Path Metric to Estimate Carrier Phase Offset in Continuous Phase Modulated Signals - A system and method for estimating carrier frequency offset Δf and carrier phase offset φ | 10-31-2013 |
20140040668 | Unit Testing and Analysis Using a Stored Reference Signal - Method and system for a test process. The method may include performing tests on one or more units under test (UUTs). At least one test on one or more UUTs may be performed. A signal may be acquired from the UUT. A reference signal may be retrieved. The reference signal may be derived from a transmitted signal characteristic of the UUT. The signal may be analyzed with respect to the reference signal. Results, useable to characterize the one or more UUTs, from performing the at least one test on the one or more UUTs may be stored. The reference signal may be derived from an initial test and may be stored for subsequent retrieval. A respective reference signal may be retrieved for all UUTs of the one or more UUTs for a respective test. The signal may be a radio frequency signal. The UUT may be a wireless mobile device. | 02-06-2014 |
20140126676 | Estimation of Sample Clock Frequency Offset Based on Error Vector Magnitude - A low complexity system and method for operating a receiver in order to estimate an offset between the actual sample clock rate 1/T | 05-08-2014 |